Perinatal deaths after sildenafil treatment of fetal growth restriction raise the issue of safety in randomised clinical trials
Niccolò Lombardi
Department of Neurosciences, Psychology, Drug Research, and Child Health, Section of Pharmacology and Toxicology, University of Florence, Tuscan Regional Centre of Pharmacovigilance, Florence, Italy
Search for more papers by this authorGiada Crescioli
Department of Neurosciences, Psychology, Drug Research, and Child Health, Section of Pharmacology and Toxicology, University of Florence, Tuscan Regional Centre of Pharmacovigilance, Florence, Italy
Search for more papers by this authorAlessandra Bettiol
Department of Neurosciences, Psychology, Drug Research, and Child Health, Section of Pharmacology and Toxicology, University of Florence, Tuscan Regional Centre of Pharmacovigilance, Florence, Italy
Search for more papers by this authorClaudia Ravaldi
CiaoLapo, Charity for Healthy Pregnancy, Stillbirth, and Perinatal Loss Support, Prato, Italy
Search for more papers by this authorCorresponding Author
Alfredo Vannacci
Department of Neurosciences, Psychology, Drug Research, and Child Health, Section of Pharmacology and Toxicology, University of Florence, Tuscan Regional Centre of Pharmacovigilance, Florence, Italy
CiaoLapo, Charity for Healthy Pregnancy, Stillbirth, and Perinatal Loss Support, Prato, Italy
Correspondence
A. Vannacci, Department of Neurosciences, Psychology, Drug Research, and Child Health, Section of Pharmacology and Toxicology, University of Florence, Viale G. Pieraccini, Florence 6-50139, Italy.
Email: [email protected]
Search for more papers by this authorNiccolò Lombardi
Department of Neurosciences, Psychology, Drug Research, and Child Health, Section of Pharmacology and Toxicology, University of Florence, Tuscan Regional Centre of Pharmacovigilance, Florence, Italy
Search for more papers by this authorGiada Crescioli
Department of Neurosciences, Psychology, Drug Research, and Child Health, Section of Pharmacology and Toxicology, University of Florence, Tuscan Regional Centre of Pharmacovigilance, Florence, Italy
Search for more papers by this authorAlessandra Bettiol
Department of Neurosciences, Psychology, Drug Research, and Child Health, Section of Pharmacology and Toxicology, University of Florence, Tuscan Regional Centre of Pharmacovigilance, Florence, Italy
Search for more papers by this authorClaudia Ravaldi
CiaoLapo, Charity for Healthy Pregnancy, Stillbirth, and Perinatal Loss Support, Prato, Italy
Search for more papers by this authorCorresponding Author
Alfredo Vannacci
Department of Neurosciences, Psychology, Drug Research, and Child Health, Section of Pharmacology and Toxicology, University of Florence, Tuscan Regional Centre of Pharmacovigilance, Florence, Italy
CiaoLapo, Charity for Healthy Pregnancy, Stillbirth, and Perinatal Loss Support, Prato, Italy
Correspondence
A. Vannacci, Department of Neurosciences, Psychology, Drug Research, and Child Health, Section of Pharmacology and Toxicology, University of Florence, Viale G. Pieraccini, Florence 6-50139, Italy.
Email: [email protected]
Search for more papers by this authorCONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES
- 1Dunn L, Greer R, Flenady V, Kumar S. Sildenafil in pregnancy: a systematic review of maternal tolerance and obstetric and perinatal outcomes. Fetal Diagn Ther. 2017; 41(2): 81-88.
- 2Sharp ACC, Jackson R, et al. Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial. Lancet Child Adolesc Health. 2018; 2(2): 93-102.
- 3Pels A, Kenny LC, Alfirevic Z, et al. STRIDER (Sildenafil TheRapy in dismal prognosis early onset fetal growth restriction): an international consortium of randomised placebo-controlled trials. BMC Pregnancy Childbirth. Dec 28 2017; 17(1): 440.
- 4Hawkes N. Trial of Viagra for fetal growth restriction is halted after baby deaths. BMJ. Jul 25 2018; 362: k3247.
- 5Groom KM, Ganzevoort W, Alfirevic Z, Lim K, Papageorghiou AT, Consortium S. Clinicians should stop prescribing sildenafil for fetal growth restriction (FGR): comment from the STRIDER Consortium. Ultrasound Obstet Gynecol: Off J Intern Soc Ultrasound Obstet Gynecol. Aug 6 2018.
10.1002/uog.19186 Google Scholar
- 6Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. Oct 7 2000; 356(9237): 1255-1259.
- 7Keogh AM, Jabbour A, Hayward CS, Macdonald PS. Clinical deterioration after sildenafil cessation in patients with pulmonary hypertension. Vasc Health Risk Manag. 2008; 4(5): 1111-1113.
- 8Sharma D, Farahbakhsh N, Shastri S, Sharma P. Intrauterine growth restriction—part 2. J Matern-Fetal Neonatal Med: Off J Euro Assoc Perinatal Med, Fed Asia Oceania Perinatal Soc, Intern Soc Perinatal Obstet. Dec 2016; 29(24): 4037-4048.
- 9Alves C, Batel-Marques F, Macedo AF. Data sources on drug safety evaluation: a review of recent published meta-analyses. Pharmacoepidemiol Drug Saf. Jan 2012; 21(1): 21-33.
- 10Joseph PD, Craig JC, Caldwell PH. Clinical trials in children. Br J Clin Pharmacol. Mar 2015; 79(3): 357-369.
- 11Kelly LE, Ohlsson A, Shah PS. Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst Rev. Aug 4 2017; 8: CD005494.
Citing Literature
